Abstract：
The coronavirus disease 2019 (COVID-19) shows high incidence of thromboembolic events in humans. In the present study, we aimed to evaluate if anticoagulation prior to COVID-19 infection may impact clinical profile, as well as mortality rate among patients hospitalized with COVID-19. The study was based on retrospective analysis of medical records of patients with laboratory confirmed SARS-CoV-2 infection. After propensity score matching (PSM), a group of 236 patients receiving any anticoagulant treatment prior to COVID-19 infection (AT group) was compared to 236 patients without previous anticoagulation (no AT group). In 180 days, the observation we noted comparable mortality rate in AT and no AT groups (38.5% vs. 41.1%, p = 0.51). Similarly, we did not observe any statistically significant differences in admission in the intensive care unit (14.1% vs. 9.6%, p = 0.20), intubation and mechanical ventilation (15.0% vs. 11.6%, p = 0.38), catecholamines usage (14.3% vs. 13.8%, p = 0.86), and bleeding rate (6.3% vs. 8.9%, p = 0.37) in both groups. Our results suggest that antithrombotic treatment prior to COVID-19 infection is unlikely to be protective for morbidity and mortality in patients hospitalized with COVID-19.
摘要：
2019年冠状病毒病（COVID-19）显示人类血栓栓塞事件的发生率很高。在本研究中,我们旨在评估COVID-19感染前的抗凝治疗是否会影响临床特征，以及COVID-19住院患者的死亡率。该研究基于对实验室确诊的SARS-CoV-2感染患者的病历的回顾性分析。在倾向得分匹配(PSM)之后，我们将236例COVID-19感染前接受抗凝治疗的患者(AT组)与236例未接受抗凝治疗的患者(无AT组)进行了比较.180天,观察到AT和无AT组的死亡率相当(38.5%vs.41.1%,p=0.51）。同样，我们没有观察到重症监护病房入院的任何统计学差异(14.1%vs.9.6%,p=0.20),插管和机械通气(15.0%vs.11.6%,p=0.38)，儿茶酚胺使用量（14.3%vs.13.8%,p=0.86),和出血率(6.3%vs.8.9%,两组p=0.37）。我们的结果表明，在COVID-19感染之前的抗血栓治疗不太可能对COVID-19住院患者的发病率和死亡率起到保护作用。
